Work

APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.3_suppl.56

Authors: Ramya Thota, Timothy Yeatman, Nishant Gandhi, Mingli Yang, Michael Schell, Lance Pflieger, Andrey Loboda, Michael Nebozhyn, Andrew Elliott, Joanne Xiu, George W. Sledge, Moh'd M. Khushman, Emil Lou, Sanjay Goel, Warren Jack Pledger

Institutions: Intermountain Healthcare, University of South Florida, Caris Life Sciences (United States), Moffitt Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Washington University in St. Louis, University of Minnesota, Rutgers Cancer Institute, Tampa General Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391096101

Cites:

Cited by:

Related to: 10